The answer to the How?
Our consulting approach builds on your studies and evidence, and integrates the value drivers and market access experiences into one strategy.
We develop focused and valuable Pricing and Market Access strategies that satisfy health technology evaluators and decision makers, and are equally beneficial for patients and physicians. These strategies enable you to successfully engage in the European Markets.
Our consulting approach builds on your studies and evidence, and integrates the value drivers and market access experiences into one strategy.
European market access challenges usually have acronyms: NICE, HAS, AMNOG, AIFA and CIMP – which give evidence of the global megatrend for rigorous assessments in reimbursement decisions of health technologies (Health Technology Assessment (HTA)).
It is not simply a question of determining how much payers will pay for drugs. It is a question, of how much of the value can you demonstrate within the clinical trial results, and how much clinical and economic justification do you have to supplement from other evidence sources.
Being members and/or coordinators of several EU teams, our team has extensive experience in supporting companies for market access, pricing and reimbursement activities. More than 200 successful submissions in many countries and across all therapeutic areas prove our wide experience and expertise.
The Pharos network is a highly specialised consulting network of 7 renowned agencies with experience in delivering a winning launch across Europe at a fair price.
Learn how we develop focused and valuable Pricing and Market Access strategies for health technology evaluators and decision makers by following our regular news from our partner network.